Gennova pegfilgrastim
Pegfilgrastim biosimilar developed by Gennova Biopharmaceuticals (Emcure). Reference product Neulasta.
About Gennova pegfilgrastim
Gennova, part of Emcure, holds the first pegfilgrastim permission in the published Indian lists, from January 2010, and one of the first anywhere in the world. Gennova also received a filgrastim permission that year.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Gennova pegfilgrastim holds an approval, these are the other pegfilgrastim biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 5 | Dr. Reddy's Laboratories (Dr. Reddy's pegfilgrastim), Lupin (Armlupeg / Lupin pegfilgrastim), USV (USV pegfilgrastim), Virchow Biotech (Virchow Biotech pegfilgrastim), Wockhardt (Wockhardt pegfilgrastim) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Gennova Biopharmaceuticals: Gennova filgrastim.
Chronology
- CDSCOJan 2010CDSCO permission granted
Sources
S014CDSCO, permissions granted in Form 46 and 46A, to 2019 Primary (regulator)
Planning pegfilgrastim biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant